1. Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice

3. CAR T-Cell Mechanism of Action

4. Current FDA-Approved Autologous CAR T-Cell Therapies

5. Current FDA-Approved Autologous CAR T-Cell Therapies (cont)

6. Selecting Patients for CAR T-Cell Therapy

7. Weighing the Decision for CAR T-Cell Therapy

8. When to Refer Patients for CAR T-Cell Therapy

9. Preparing for CAR T-Cell Therapy: The Patient's Journey

10. CAR T-Cell Therapy Production

11. Considerations for CAR T-Cell Administration

12. Essentials for CAR T-Cell Therapy

13. Acute AEs of CAR T-Cell Therapy

14. Early Monitoring of CAR T-Cell Toxicity

15. Documenting Acute Toxicity for Rapid Response

16. Managing Toxicity: Keeping Pace With Best Practices

17. Grading CRS

18. Grading ICANS

19. Management of CRS

20. Management of ICANS

21. Better Communication = Better Outcomes

22. Late Toxicities of CAR T-Cell Therapy

23. Key Takeaways

24. Abbreviations

25. Abbreviations (cont)